Financials
Financial year 2025
Revenue
€ 330 million
Profit
Growing€ 10.2 million
▲ 9% vs 2024
Debts
Low€ 136.5 million
▲ 12% vs 2024
JOHNSON & JOHNSON MEDICAL from Machelen (Brab.), company number BE0425967580, closed financial year 2025 with a result of € 10.2 million after tax. For that financial year JOHNSON & JOHNSON MEDICAL recorded revenue of € 330 million and equity of € 80.2 million. Compared with financial year 2024, the result moved from € 9.4 million to € 10.2 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 6, 2026.
What happened at JOHNSON & JOHNSON MEDICAL?
What happened at JOHNSON & JOHNSON MEDICAL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Bram Van Elsen stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 10.2 million (▲ 9% vs 2024). Source: NBB ↗
- Katrien Lindemans stepped down as director. NBB
- Bert Van Opdenbosch stepped down as director. NBB
- Bram Van Elsen became a director. NBB
- Fabrice Degenève stepped down as director. NBB
- Fabrice Degenève became a director. NBB
- Katrien Lindemans became a director. NBB
In short
From € 4.7 million profit in 2021 to € 10.2 million profit in 2025.
Paid € 15.6 million in corporate taxes since 2021.
Best year ever: 2025, with € 10.2 million profit.
Paid out € 35 million in dividends to the owners in total.
A new publication or filing at JOHNSON & JOHNSON MEDICAL? We notify you, reason included.
Follow JOHNSON & JOHNSON MEDICALNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
It owns 100% of JJSV Belgium itself.
Directors
According to the 2025 annual accounts
Bram Van Elsen
Managing director
since 2026 · until 2031
Katrien Lindemans
Managing director
since 2021 · until 2026
Fabrice Degenève
Managing director
since 2024 · until 2026
Bert Van Opdenbosch
Managing director
since 2021 · until 2026
Establishments
Establishment units
Physical locations of this company
Leonardo da Vincilaan 15
1831 Machelen (Brab.)
Antwerpseweg 15-17
2340 Beerse
Active since 1 January 2013
Turnhoutseweg 30
2340 Beerse
Active since 1 August 2013
Antwerpseweg 19-21
2340 Beerse
Active since 31 March 2014
Rue du Luxembourg(CO) 5
6180 Courcelles
Active since 1 November 2014
de Meeûssquare 23
1000 Brussel
Active since 1 June 2015
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.
OMRIX BIOPHARMACEUTICALS
€ 107 million revenue · 2025
BELGIUM - LUXEMBOURG ORACLE USER GROUP
JJSV Belgium same network
€ 7.6 million revenue · 2024
GMED HEALTHCARE
€ 3,610.8 million revenue · 2025
DePuy Synthes (Belgium)
+1 more
Details
- Company number
- 0425.967.580
- VAT number
- BE 0425.967.580
- Registered office
- Leonardo da Vincilaan 15, 1831 Machelen (Brab.)
- Names & denominations
- JOHNSON & JOHNSON MEDICAL · J&J Medical, Ethicon, CSS, DePuy Synthes, J&J Vision, Biosense Webster
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 7 June 1984
- Peppol
- Active · Active since 18 Dec 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Groothandel in farmaceutische producten
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels